OnKure Therapeutics, Inc.
OKUR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$131.16M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $131.16 Million |
|---|---|
| Enterprise Value | $-34,420,064.00 |
| Earnings per Share | $-4.4 |
| Beta | 0.3 |
| Outstanding Shares | 49,869,177 |
Return
| Return on Equity | -8.92% |
|---|---|
| Return on Assets | -8.56% |
| Return on Invested Capital | -35.98% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.69 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.54
Consensus analyst estimateRevenue Estimate
$166,667
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.41
Consensus analyst estimateRevenue Estimate
$166,667
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.04%▼ 131.21% |
|---|---|
| Total Invested | $159.28M▲ 39.79% |
| Investors Holding | 76▲ 25.00% |
About Reneo Pharmaceuticals Inc
18 employees
CEO: Nicholas A. Saccomano
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produc...